Genelux (NASDAQ:GNLX – Get Free Report) is anticipated to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Genelux Stock Performance
Shares of GNLX opened at $3.03 on Friday. The company’s 50-day simple moving average is $4.05 and its 200-day simple moving average is $3.09. Genelux has a 1 year low of $1.60 and a 1 year high of $6.50. The stock has a market capitalization of $104.65 million, a PE ratio of -3.19 and a beta of -1.41.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Genelux in a research note on Tuesday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Genelux currently has an average rating of “Buy” and a consensus target price of $18.25.
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Read More
- Five stocks we like better than Genelux
- Airline Stocks – Top Airline Stocks to Buy Now
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Top 3 Beverage Stocks Pouring Out Profits
- How to Read Stock Charts for Beginners
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
